Name: TBPH Income Statement - Theravance Biopharma Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

TBPH - Theravance Biopharma, Inc.

USD | NASDAQ | Healthcare

TBPH Income Statement - Theravance Biopharma Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Revenues
Revenues	17.7	45.9	20.0	26.2	15.4	18.8	16.9	14.3	14.5	17.6	15.7	13.7	10.4	14.6	12.5	11.1

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
Revenues
Revenues	109.8	107.5	64.4	57.4	51.3	55.3	71.9	73.4	60.4	15.4	48.6	42.1	11.7	0.2	130.1
Cost of Revenue	-	-	-	-	-	-	-	-	-	6.0	2.9	4.7	4.1	0.0	0.0
Gross Profit	-	-	-	-	-	-	-	-	-	9.4	45.8	37.5	7.6	0.2	130.1
Operating Expenses
Research & Development	31.8	37.4	37.6	40.6	63.4	193.7	261.0	219.2	201.3	173.9	141.7	129.2	168.5	120.6	114.0
Operating Income
Operating Income	1.3	(3.6)	(46.9)	(56.0)	(92.0)	(257.8)	(297.6)	(251.9)	(238.8)	(260.1)	(180.5)	(181.9)	(232.5)	(156.3)
Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax & Net
Income Tax Expense	22.4	23.4	11.8	5.9	0.0	(0.2)	(8.5)	(5.2)	(10.6)	13.7	10.1	1.0	6.4	0.0	0.0
Per Share
EPS Basic	2.23	2.10	(1.15)	(1.00)	11.85	(2.87)	(4.46)	(4.25)	-	-	-	-	-	-	-
EPS Diluted
Supplementary Data
EBITDA	-	(2.1)	(45.3)	(54.1)	(89.4)	(254.3)	(294.3)	(248.6)	(235.6)	(256.1)	(177.3)	(178.9)	(229.3)	(153.6)	(6.3)
EBIT

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	5.8	7.4	8.1	10.5	11.5	9.5	9.3	10.0	9.0	8.3	8.3	9.4	14.6	15.3	9.9	14.9	23.3	31.2	43.7	51.1	67.6	65.2	67.4	62.4	66.0	67.0	52.0	46.4	53.8	52.3	52.7	48.6	47.8	51.1	39.3	42.9	40.6	42.0	32.0	32.1
Selling General & Administrative	17.7	18.5	18.3	18.4	18.4	18.5	16.9	17.1	16.7	15.5	16.1	19.3	19.2	16.7	16.3	16.2
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	27.2	25.9	26.4	28.9	29.8	28.0	27.7	30.0	25.7	23.8	24.5	29.9	35.3	32.1	26.7	34.2

Operating Income
Operating Income	(9.5)	20.0	(6.5)	(2.7)	(14.4)	(9.2)	(10.8)	(15.7)	(11.2)	(6.2)	(8.8)	(16.1)	(24.9)	(17.4)	(14.2)	(23.1)	(37.2)	(56.2)	(53.6)	(64.1)	(83.9)	(76.4)	(76.6)	(72.2)	(72.5)	(70.6)	(65.2)	(42.5)	(73.7)	(62.6)	(62.5)	(48.7)	(65.0)	(79.2)	(57.0)	(65.1)	(58.8)	(57.8)	(33.5)	(47.5)

Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	0.6	0.6	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	1.5	2.1	2.1	(17.1)
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28.1	25.1
Other Non-Operating Income	3.0	3.6	4.1	1.5	0.9	0.9	1.4	1.1	1.4	1.8	1.8	2.5	3.0	3.7	2.8	2.4	(0.4)
Pre-Tax Income	(6.5)	73.1	(2.9)	73.2	(14.1)	(8.9)	(10.1)	(15.2)	(10.4)	(5.0)	(7.6)	(14.2)	(22.5)	(14.3)	(16.0)	(22.8)

Tax & Net
Income Tax Expense	(1.5)	12.0	(6.5)	18.4	(0.6)	6.6	2.6	1.3	1.3	3.5	1.4	1.5	(0.4)	-	-	(0.0)	0.5	(0.2)	(0.0)	(0.2)	0.2	(8.8)	0.1	0.0	0.1	0.0	(5.6)	0.2	0.1	(3.3)	(0.7)	(6.8)	0.1	7.0	0.9	0.5	5.4	8.6	0.8	0.0
Net Income From Continuing Ops	(4.9)	61.0	3.6	54.8	(13.6)	(15.5)	(12.7)	(16.5)	(11.7)	(8.5)	(9.0)	(15.6)	(22.1)	(13.7)	(16.0)	(22.8)	(40.3)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	3.4	932.7	14.6	14.3
Net Income	(4.9)	61.0	3.6	54.8	(13.6)	(15.5)	(12.7)	(16.5)	(11.7)	(8.5)	(9.0)	(15.6)	(22.1)	(10.4)	916.6	(8.2)	(25.9)
Net Income Attributable To Parent	(4.9)	61.0	3.6	54.8	(13.6)	(15.5)	(12.7)	(16.5)	(11.7)	(8.5)	(9.0)	(15.6)	(22.1)	(10.4)	916.6	(8.2)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(4.9)	61.0	3.6	54.8	(13.6)	(15.5)	(12.7)	(16.5)	(11.7)	(8.5)	(9.0)	(15.6)	(22.1)	(10.4)	916.6

Per Share
EPS Basic	(0.10)	-	0.07	1.09	(0.27)	-	(0.26)	(0.34)	(0.24)	-	(0.17)	(0.28)	(0.35)	-	12.14	(0.11)	(0.34)	-	(0.48)	(0.80)	(1.24)	-	(1.16)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Diluted	(0.10)	-	0.07	1.08	(0.27)	-	(0.26)	(0.34)	(0.24)	-	(0.17)	(0.28)	(0.35)	-	12.14	(0.11)	(0.34)	-
Shares Basic	51.3	-	50.5	50.2	49.7	-	49.0	48.7	48.3	-	52.4	56.7	62.9	-	75.5	76.3	75.2	-
Shares Diluted	51.3	-	51.9	50.7	49.7	-	49.0	48.7	48.3	-	52.4	56.7	62.9	-	75.5	76.3	75.2	-

Supplementary Data
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(72.4)	-	-	-	(64.0)	-	-	-	(57.7)	-	-	-
EBIT	(9.5)	20.0	(6.5)	(2.7)	(14.4)	(9.2)	(10.8)	(15.7)	(11.2)	(6.2)	(8.8)	(16.1)	(24.9)	(17.4)	(14.2)	(23.1)	(37.2)	(56.2)	(53.6)